1
|
Sharma B, Bekerman E, Truong H, Lee J, Gamez-Guerrero M, Boopathy A, Mital R, Huang KB, Ahmadi-Erber S, Wimmer R, Schulha S, Lauterbach H, Orlinger K, Suthram S, Lewis MG, Blair W, Makadzange T, Geleziunas R, Murry JP, Schmidt S. Arenavirus-Based Vectors Generate Robust SIV Immunity in Non-Human Primates. Vaccines (Basel) 2024; 12:735. [PMID: 39066373 PMCID: PMC11281402 DOI: 10.3390/vaccines12070735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2024] [Revised: 06/20/2024] [Accepted: 06/27/2024] [Indexed: 07/28/2024] Open
Abstract
Arenavirus-based vectors are being investigated as therapeutic vaccine candidates with the potential to elicit robust CD8 T-cell responses. We compared the immunogenicity of replicating (artPICV and artLCMV) and non-replicating (rPICV and rLCMV) arenavirus-based vectors expressing simian immunodeficiency virus (SIV) Gag and Envelope (Env) immunogens in treatment-naïve non-human primates. Heterologous regimens with non-replicating and replicating vectors elicited more robust SIV IFN-γ responses than a homologous regimen, and replicating vectors elicited significantly higher cellular immunogenicity than non-replicating vectors. The heterologous regimen elicited high anti-Env antibody titers when administered intravenously, with replicating vectors inducing significantly higher titers than non-replicating vectors. Intramuscular immunization resulted in more durable antibody responses than intravenous immunization for both vector platforms, with no difference between the replicating and non-replicating vectors. Overall, both replicating and non-replicating arenavirus vectors generated robust T- and B-cell-mediated immunity to SIV antigens in treatment-naïve non-human primates, supporting further evaluation of these vectors in a clinical setting for HIV therapy.
Collapse
Affiliation(s)
- Bhawna Sharma
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (E.B.); (H.T.); (J.L.); (M.G.-G.); (A.B.); (R.M.); (S.S.); (W.B.); (T.M.); (R.G.); (J.P.M.)
| | - Elena Bekerman
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (E.B.); (H.T.); (J.L.); (M.G.-G.); (A.B.); (R.M.); (S.S.); (W.B.); (T.M.); (R.G.); (J.P.M.)
| | - Hoa Truong
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (E.B.); (H.T.); (J.L.); (M.G.-G.); (A.B.); (R.M.); (S.S.); (W.B.); (T.M.); (R.G.); (J.P.M.)
| | - Johnny Lee
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (E.B.); (H.T.); (J.L.); (M.G.-G.); (A.B.); (R.M.); (S.S.); (W.B.); (T.M.); (R.G.); (J.P.M.)
| | - Maria Gamez-Guerrero
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (E.B.); (H.T.); (J.L.); (M.G.-G.); (A.B.); (R.M.); (S.S.); (W.B.); (T.M.); (R.G.); (J.P.M.)
| | - Archana Boopathy
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (E.B.); (H.T.); (J.L.); (M.G.-G.); (A.B.); (R.M.); (S.S.); (W.B.); (T.M.); (R.G.); (J.P.M.)
| | - Rohit Mital
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (E.B.); (H.T.); (J.L.); (M.G.-G.); (A.B.); (R.M.); (S.S.); (W.B.); (T.M.); (R.G.); (J.P.M.)
| | - Katell Bidet Huang
- Hookipa Pharma Inc., New York, NY 10018, USA; (K.B.H.); (S.A.-E.); (R.W.); (S.S.); (H.L.); (K.O.)
| | - Sarah Ahmadi-Erber
- Hookipa Pharma Inc., New York, NY 10018, USA; (K.B.H.); (S.A.-E.); (R.W.); (S.S.); (H.L.); (K.O.)
| | - Raphaela Wimmer
- Hookipa Pharma Inc., New York, NY 10018, USA; (K.B.H.); (S.A.-E.); (R.W.); (S.S.); (H.L.); (K.O.)
| | - Sophie Schulha
- Hookipa Pharma Inc., New York, NY 10018, USA; (K.B.H.); (S.A.-E.); (R.W.); (S.S.); (H.L.); (K.O.)
| | - Henning Lauterbach
- Hookipa Pharma Inc., New York, NY 10018, USA; (K.B.H.); (S.A.-E.); (R.W.); (S.S.); (H.L.); (K.O.)
| | - Klaus Orlinger
- Hookipa Pharma Inc., New York, NY 10018, USA; (K.B.H.); (S.A.-E.); (R.W.); (S.S.); (H.L.); (K.O.)
| | - Silpa Suthram
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (E.B.); (H.T.); (J.L.); (M.G.-G.); (A.B.); (R.M.); (S.S.); (W.B.); (T.M.); (R.G.); (J.P.M.)
| | | | - Wade Blair
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (E.B.); (H.T.); (J.L.); (M.G.-G.); (A.B.); (R.M.); (S.S.); (W.B.); (T.M.); (R.G.); (J.P.M.)
| | - Tariro Makadzange
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (E.B.); (H.T.); (J.L.); (M.G.-G.); (A.B.); (R.M.); (S.S.); (W.B.); (T.M.); (R.G.); (J.P.M.)
| | - Romas Geleziunas
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (E.B.); (H.T.); (J.L.); (M.G.-G.); (A.B.); (R.M.); (S.S.); (W.B.); (T.M.); (R.G.); (J.P.M.)
| | - Jeffrey P. Murry
- Gilead Sciences, Inc., Foster City, CA 94404, USA; (E.B.); (H.T.); (J.L.); (M.G.-G.); (A.B.); (R.M.); (S.S.); (W.B.); (T.M.); (R.G.); (J.P.M.)
| | - Sarah Schmidt
- Hookipa Pharma Inc., New York, NY 10018, USA; (K.B.H.); (S.A.-E.); (R.W.); (S.S.); (H.L.); (K.O.)
| |
Collapse
|
2
|
Lafoux B, Baillet N, Picard C, Fourcaud G, Borges-Cardoso V, Reynard S, Journeaux A, Germain C, Perthame E, Mateo M, Hortion J, Carnec X, Pietrosemoli N, Moroso M, Lacroix O, Jourjon O, Barron S, Vallve A, Duthey A, Jacquot F, Barrot L, Dirheimer M, Raoul H, Nougier C, Baize S. Hemostasis defects underlying the hemorrhagic syndrome caused by mammarenaviruses in a cynomolgus macaque model. Blood 2023; 142:2092-2104. [PMID: 37699247 DOI: 10.1182/blood.2023020351] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Revised: 07/18/2023] [Accepted: 08/15/2023] [Indexed: 09/14/2023] Open
Abstract
Viral hemorrhagic fevers (HF) are a group of acute febrile diseases with high mortality rates. Although hemostatic dysfunction appears to be a major determinant of the severity of the disease, it is still unclear what pathogenic mechanisms lead to it. In clinical studies it is found that arenaviruses, such as Lassa, Machupo, and Guanarito viruses cause HF that vary in symptoms and biological alterations. In this study we aimed to characterize the hemostatic dysfunction induced by arenaviral HF to determine its implication in the severity of the disease and to elucidate the origin of this syndrome. We found that lethal infection with Machupo, Guanarito, and Lassa viruses is associated with cutaneomucosal, cerebral, digestive, and pulmonary hemorrhages. The affected animals developed a severe alteration of the coagulation system, which was concomitant with acute hepatitis, minor deficit of hepatic factor synthesis, presence of a plasmatic inhibitor of coagulation, and dysfunction of the fibrinolytic system. Despite signs of increased vascular permeability, endothelial cell infection was not a determinant factor of the hemorrhagic syndrome. There were also alterations of the primary hemostasis during lethal infection, with moderate to severe thrombocytopenia and platelet dysfunction. Finally, we show that lethal infection is accompanied by a reduced hematopoietic potential of the bone marrow. This study provides an unprecedented characterization of the hemostasis defects induced by several highly pathogenic arenaviruses.
Collapse
Affiliation(s)
- Blaise Lafoux
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Nicolas Baillet
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Caroline Picard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Gustave Fourcaud
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Virginie Borges-Cardoso
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Stéphanie Reynard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Alexandra Journeaux
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Clara Germain
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Emeline Perthame
- Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Paris, France
| | - Mathieu Mateo
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Jimmy Hortion
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Xavier Carnec
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Natalia Pietrosemoli
- Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Paris, France
| | - Marie Moroso
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | - Orianne Lacroix
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | - Ophélie Jourjon
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | - Stéphane Barron
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | - Audrey Vallve
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | - Aurélie Duthey
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | | | - Laura Barrot
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | - Manon Dirheimer
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | - Hervé Raoul
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | - Christophe Nougier
- Service d'hématologie Biologique, Centre de Pathologie et Biologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
| | - Sylvain Baize
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| |
Collapse
|